

Preclinical Pharmacokinetic and Pharmacodynamic Characterization of EDP-938, a Novel and Potent Non-Fusion Replication Inhibitor of Respiratory Syncytial Virus (RSV)

Li-Juan Jiang, Lisha Xu, Meng Huang, Shucha Zhang, Yang Li, Tianzhu Indy Zang, Jonathan Kibel, Madison Adams, Noelle Labrecque, Michael H. J. Rhodin, Nicole V. McAllister, Kai Lin, In Jong Kim, Yat Sun Or
Enanta Pharmaceuticals., Inc. Watertown, MA 02472 USA

To request a pdf of this poster, please email: ljjiang@enanta.com

ABSTRACT

Background: Respiratory syncytial virus (RSV) infection presents a significant health challenge in young children, the elderly, and immunocompromised patients. To date, there are no effective treatments available. EDP-938 was designed to meet this unmet medical need and is currently in Phase 2 clinical trials. Herein we report its preclinical pharmacokinetic (PK) and pharmacodynamic (PD) properties. **Method:** The pharmacokinetics of EDP-938 following single intravenous and oral doses were determined in mice, rats, dogs, and monkeys. *In vitro* cellular permeability and metabolic stability were assayed using Caco-2 cells and human liver microsomes, respectively. *In vivo* pharmacodynamic efficacy of EDP-938 was conducted in an African green monkey model, in which animals experimentally challenged with RSV were orally dosed twice daily with 100 mg/kg EDP-938 for 6 days starting 24 hours prior to infection. **Results:** EDP-938 was well absorbed in the preclinical species with oral bioavailability values ranging from 27.1% in dogs to 35.4% in mice, 35.7% in rats, and 39.5% in monkeys, after a single oral dose when formulated in 0.5% methylcellulose. EDP-938 showed a moderate *in vitro* permeability of 3.6×10^{-6} cm/sec in Caco-2 cells. Based on the outcome of these absorption studies, EDP-938 was projected to have good oral absorption in humans. EDP-938 had low intrinsic clearance of 5 μ L/min/mg in human liver microsomes. Moreover, EDP-938 demonstrated potent antiviral efficacy in an African green monkey model of RSV infection. In untreated monkeys the RSV RNA viral load in the bronchoalveolar lavage fluid peaked at 10^6 copies/mL on day 5 post infection, by comparison in animals treated with EDP-938 the viral load was below the limit of detection by day 3 post infection. The PK/PD modeling suggested that plasma trough concentrations $\geq 10 \times EC_{90}$ led to >4-log viral load reduction in EDP-938-treated monkeys. **Conclusion:** The favorable preclinical PK and PD properties of EDP-938 support its further clinical development as a novel treatment for RSV infection.

INTRODUCTION

EDP-938, a novel and potent non-fusion replication inhibitor of RSV, is currently in Phase 2 clinical development for the treatment of RSV infection. EDP-938 achieved highly statistically significant ($p < 0.001$) reductions in RSV viral load and RSV-associated clinical symptoms compared to placebo in the Phase 2a RSV challenge study in healthy adults¹.

METHOD

In Vitro Metabolic Stability

- EDP-938 or control (1 μ M) incubated with liver microsomes (1 mg/mL) in PBS (100 mM, pH 7.4), MgCl₂ (2 mM), EDTA (1 mM) and NADPH (2 mM) at 37 °C.
- Samples were collected at 0, 5, 10, 20, 30, 45 and 60 mins for LC-MS/MS and Intrinsic clearance calculation.

In Vivo Pharmacokinetics

- IV dose: 2 - 5 mg/kg; PO dose: 10 - 25 mg/kg
- PO formulation: 0.5% methylcellulose in water
- In Vivo Efficacy in African Green Monkeys (AGMs)**
 - AGMs were inoculated with 2×10^5 PFU of RSV A2 on Day 0. EDP-938 (100 mg/kg BID, n=4) or vehicle control (n=4) was given orally for 6 days starting 24 hours prior to infection.
 - Samples were taken on Days 1, 3, 5, 7, 11 and 15 through bronchoalveolar lavage (BAL) and nasopharyngeal (NP) swab to measure RSV levels.

RESULTS

A. EDP-938 *In Vitro* Metabolic Stability


Cl _{int} , <i>in vitro</i> (μ L/min/mg)				
Human	Monkey	Dog	Rat	Mouse
5.0	18.3	5.0	42.8	11.2

RESULTS (continued)

B. EDP-938 Preclinical Pharmacokinetics Across Different Species

Species	Route	Dose (mg/kg)	C _{max} (μ g/mL)	T _{max} (hr)	T _{1/2} (hr)	V _z (L/kg)	CL (L/hr/kg)	AUC _{0-∞} (μ g-hr/mL)	F (%)
Mouse	i.v.	5	3.79	--	0.81	1.13	0.97	5.17	--
	p.o.	25	3.18	1.0	2.54	--	--	9.14	35.4
Rat	i.v.	2	0.98	--	1.06	3.66	2.38	0.84	--
	p.o.	10	0.47	0.5	1.75	--	--	1.50	35.7
Monkey	i.v.	5	3.74	--	4.15	4.65	0.77	6.54	--
	p.o.	25	1.05	6.0	5.33	--	--	12.91	39.5
Dog	i.v.	5	3.91	--	2.46	2.07	0.20	29.02	--
	p.o.	25	2.82	4.0	5.67	--	--	39.30	27.1

C. EDP-938 *In Vivo* Efficacy in AGMs



RESULTS (continued)

D. EDP-938 Steady State Plasma Trough Concentrations in AGMs

AGM #	Plasma C ₁₂ (ng/mL)	Fold EC ₉₀
#1	580	10.5
#2	526	9.5
#3	1150	20.7
#4	994	17.9
Average	812.5 ± 307.1	14.6 ± 5.5

EDP-938 *in vitro* EC₉₀ = 55.5 ng/mL against RSV A2 in Vero cells

CONCLUSIONS

- EDP-938 was well absorbed in the preclinical species with low intrinsic clearance in human liver microsomes.
- EDP-938 demonstrated potent antiviral efficacy in an AGM RSV infection model.
- The PK/PD modeling suggested that EDP-938 plasma trough concentrations $\geq 10 \times RSV EC_{90}$ were associated with >4-log RSV viral load reduction in EDP-938-treated AGMs.
- The favorable preclinical PK and PD properties of EDP-938 support its further clinical development as a novel treatment for RSV infection.

¹ Coakley, et al. "EDP-938, a Novel RSV N-Inhibitor, Administered Once or Twice Daily Was Safe and Demonstrated Robust Antiviral and Clinical Efficacy in a Healthy Volunteer Challenge Study", #LB6, IDWeek™ 2019